All News
Filter News
Found 808,615 articles
-
Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results
11/3/2017
Net loss for the quarter ended September 30, 2017 was $3.8 million, or loss per share of $0.29, compared to a net loss of $1.3 million, or loss per share of $0.19, for the third quarter of 2016.
-
Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results
11/3/2017
Adamas reported a net loss of $23.4 million, or $1.04 per share, basic and diluted, for the third quarter of 2017, compared to a net loss of $14.4 million, or $0.66 per share, basic and diluted, for the third quarter of 2016.
-
Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017
11/3/2017
A live audio webcast of the call will be available on the Presentations section of the Company’s website.
-
Cryoport Revenue Up 52%; Driven by BioPharma
11/3/2017
CryoPort today announced financial results for the three- and nine-month periods ended September 30, 2017.
-
Corcept Therapeutics Announces Third Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
11/3/2017
Third quarter revenue of $42.8 million, an increase of 97 percent from third quarter 2016.
-
Catabasis Pharmaceuticals to Report Third Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, November 9
11/3/2017
Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 4:30pm ET to provide an update on corporate developments and to discuss third quarter financial results.
-
Dova Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 9, 2017
11/3/2017
A question-and-answer session will follow Dova's remarks.
-
Cara Therapeutics Reports Third Quarter 2017 Financial Results
11/3/2017
Management to host conference call today at 4:30 p.m. ET.
-
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update
11/3/2017
At September 30, 2017, Corvus had cash, cash equivalents and marketable securities totaling $99.7 million compared to cash, cash equivalents and marketable securities of $134.9 million at December 31, 2016.
-
DATATRAK Reports Third Quarter Results of 2017
11/3/2017
DATATRAK reduced its direct costs by 15% and its SG&A expenses by 1% for the three months ended September 30, 2017 compared to the three months ended September 30, 2016.
-
Dynavax Reports Third Quarter 2017 Financial Results
11/3/2017
Cash, cash equivalents and marketable securities were $191.7 million at September 30, 2017 compared to $81.4 million at December 31, 2016.
-
Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance
11/3/2017
For Q3 2017, Total revenues were $149.4 million, an increase of 5% as compared to 2016.
-
Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results
11/3/2017
The conference call will be held on Tuesday, November 7, 2017, at 5:00 p.m. ET to discuss a corporate update and results for the third quarter of 2017.
-
Flex Pharma to Report Third Quarter 2017 Results on November 6, 2017
11/3/2017
The Company will host a conference call and webcast at 8:45 a.m. ET to discuss third quarter 2017 financial results and provide a business update.
-
Fluidigm Announces Third Quarter Financial Results and Operational Progress
11/3/2017
Total revenue for the third quarter was $24.7 million, an increase of 12% from $22.2 million in the third quarter of 2016 and an increase of 3% from $23.9 million in the second quarter of 2017.
-
Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results
11/3/2017
Cash, cash equivalents and marketable securities totaled $259.4 million at September 30, 2017, compared with $197.3 million at December 31, 2016.
-
IntelGenx to Report Third Quarter 2017 Financial Results on November 9, 2017 - Conference Call to Follow
11/3/2017
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update.
-
ImmuCell to Announce Financial Results for Third Quarter of 2017
11/3/2017
The Company has scheduled a conference call that same day, Monday, November 13, 2017, at 4:30 PM ET to review the results.
-
ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results
11/3/2017
Revenues for the quarter ended September 30, 2017 were $8.5 million, compared to $7.7 million for the quarter ended September 30, 2016.
-
Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update
11/3/2017
Total revenues were $86.8 million in the third quarter of 2017 compared to $66.1 million in the third quarter of 2016.